Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and CTLA-4 are promising tools against NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.